Dr hab. n. med. Jakub Dobruch, FEBU – Liquid Biopsy

Dr hab. n. med. Jakub Dobruch, FEBU. Urological Review, The Polish Association of Urology bimonthly magazine. No. 5/2016

Liquid Biopsy is an example of a new kind of research that could revolutionize cancer detection and treatment of patients affected.

By | November 14th, 2016|Medical publications|0 Comments

ASCO 2016

“Tumor cell-free DNA copy number instability (CNI) predicts therapeutic response to immunotherapy prior to cycle 2” , was presented at the American Society of Clinical Oncology (‘ASCO’) Annual Meeting 2016 on 5 June 2016 at McCormick Place in Chicago, Illinois. The abstract and poster presentation describe the work conducted by independent oncologists in a blinded [...]

By | November 3rd, 2016|Events|0 Comments

Chronix Biomedical updates on progress with prostate and pancreatic cancer validation studies

Chronix Biomedical

Chronix Biomedical, Inc., a developer of novel cancer blood-based molecular diagnostics, is pleased to update investors on the progress of two clinical studies...

By | November 3rd, 2016|Chronix news|0 Comments

First published results in breast cancer

Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 2010; 8:335-42.

Chronix has first used the NGS technology for investigation into the use in breast cancer with very promising results.

By | November 3rd, 2016|Medical publications|0 Comments

HPV Genotyping and Treatment Outcome Predictions

Urnovitz, HB et al. Detection of novel HPV mutations and chromosomal number imbalance (CNI) in laryngeal cancer using next-generation sequencing (NGS). J ClinOncol 32:5s, 2014 (suppl; abstr 6072).

The detection of novel HPV mutations and CNI analysis in a single NGS run on HPV-related diseases provides important information into viral-host dynamics while generating biomarkers that can be correlated with treatment outcomes.

By | November 3rd, 2016|Medical publications|0 Comments

Breast Cancer Liquid Biopsy Screening Test

Beck, J. et al. Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. J ClinOncol 31, 2013 (suppl; abstr 11013).

Using comparative massive parallel sequencing of cfDNA from cancer patients vs. controls, we were able to show that a 16-region model based on CNV, is useful to distinguish patients with breast cancer from matched controls.

By | November 3rd, 2016|Medical publications|0 Comments

Minimal Residual Disease in Breast Cancer

Urnovitz, HB et al. Modulation of breast cancer cell-free DNA with surgical resection. J ClinOncol 31, 2013 (suppl; abstr 11060).

In this study, we sought to determine whether cfDNA decreases after surgery in patients with operable invasive breast cancer. Serum was collected before and 1-4 weeks after surgery from 16 breast cancer patients and also from 24 age and gender matched controls.

By | November 3rd, 2016|Medical publications|0 Comments

NGS Animal Model for MRD in Breast Cancer

Beck, J. et al. Structural variation in mammary carcinomas and their detection in cell-free plasma DNA. PLOS One 2013 (10.1371/journal.pone.0075485).

Mammary tumors are the most frequent cancers in female dogs exhibiting a variety of histopathological differences. There is lack of knowledge about the genomes of these common dog tumors. Five tumors of three different histological subtypes were evaluated.

By | November 3rd, 2016|Medical publications|0 Comments

NGS of prostate cancer

Schütz, E. et al. Comparative analysis of the chromosomal origins of circulating nucleic acids in breast and prostate cancer. J ClinOncol 28:15s, 2010 (suppl; abstr 10505).

The aim of this study was to find signature CNA sequences from patients with breast cancer (BCa) or prostate cancer (PCa) compared to healthy controls, with respect to their predictive potential, as well as to provide new insights into tumor biology.

By | November 3rd, 2016|Medical publications|0 Comments

Breast Cancer cfDNA with NGS

Beck, J. et al. Next Generation Sequencing of Serum Circulating Nucleic Acids from Invasive Ductal Breast Cancer Patients Reveals Differences to Healthy and Non-malignant Controls. Mol. Cancer Res. 2010; 8: 385-92.

Circulating nucleic acids (CNA) isolated from serum or plasma are increasingly recognized as biomarkers for cancers.We report specific DNA-transposable element sequences that could discriminate all stages of invasive ductal breast carcinoma with significant specificity and sensitivity.

By | November 3rd, 2016|Medical publications|0 Comments